Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Cambridge Antibody Technology Group -- Ignore unavailable to you. Want to Upgrade?

To: Jongmans who wrote (67)	2/21/2000 8:56:00 AM
From: paradigm7241	Respond to of 625

Correct...Morphosys has 3.5 million shares outstanding I was reading the IPO document and misunderstood the DM 17.1 million as shares outstanding when it appears to have meant a market cap of 17.1 million German currency on the date of the IPO. MOR is now at 420.00 USD giving it a 1.47 billion USD market cap. Still far too high compared to CAT's 732 million USD market cap. Clearly, a major reason for MOR's run is their very small float. Had I known this number before I personally would have invested even though I think CAT has the superior collaborators, market positioning and products in clinical trials. CAT will eventually catch up but we will need to execute patience as the float must be quite large which means they will need (a) become more visible to a large investor pool (i.e. the US) and (b) shake out any weak hands that still exist. PM